Johnson & Johnson (NYSE:JNJ) Shares Sold by Addenda Capital Inc.

Addenda Capital Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,807 shares of the company’s stock after selling 119 shares during the quarter. Addenda Capital Inc.’s holdings in Johnson & Johnson were worth $6,046,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Priebe Wealth Holdings LLC raised its holdings in shares of Johnson & Johnson by 39.3% in the 4th quarter. Priebe Wealth Holdings LLC now owns 1,817 shares of the company’s stock valued at $263,000 after purchasing an additional 513 shares in the last quarter. Hoese & Co LLP raised its stake in Johnson & Johnson by 15.6% in the fourth quarter. Hoese & Co LLP now owns 2,502 shares of the company’s stock valued at $362,000 after buying an additional 338 shares in the last quarter. Wealthquest Corp lifted its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Wealthquest Corp now owns 9,277 shares of the company’s stock worth $1,342,000 after buying an additional 115 shares during the last quarter. Amplius Wealth Advisors LLC boosted its position in shares of Johnson & Johnson by 16.1% during the 4th quarter. Amplius Wealth Advisors LLC now owns 5,234 shares of the company’s stock worth $757,000 after acquiring an additional 727 shares in the last quarter. Finally, Gemmer Asset Management LLC increased its holdings in shares of Johnson & Johnson by 11.0% in the 4th quarter. Gemmer Asset Management LLC now owns 9,298 shares of the company’s stock valued at $1,345,000 after acquiring an additional 923 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Bank of America decreased their target price on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a research note on Friday, January 17th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $173.27.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $145.39 on Thursday. The firm has a market cap of $350.04 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.50 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The firm’s fifty day moving average price is $148.26 and its 200 day moving average price is $156.12.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period in the prior year, the company posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.